Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Место диуретиков в терапии артериальной гипертонии: фокус на новый петлевой диуретик торасемид
Место диуретиков в терапии артериальной гипертонии: фокус на новый петлевой диуретик торасемид
Леонова М.В. Место диуретиков в терапии артериальной гипертонии: фокус на новый петлевой диуретик торасемид. Consilium Medicum. 2015; 17 (10): 23–26. DOI: 10.26442/2075-1753_2015.10.23-27
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Представлен обзор фармакоэпидемиологии применения диуретиков для лечения артериальной гипертонии, место петлевых диуретиков, в частности торасемида.
Ключевые слова: диуретики, торасемид, артериальная гипертония, фармакоэпидемиология.
Ключевые слова: диуретики, торасемид, артериальная гипертония, фармакоэпидемиология.
________________________________________________
We show the pharmacoepidemiology review concerning diuretics usage for the treatment of arterial hypertension, the role of loop diuretics, in particular torasemide.
Key words: diuretics, torasemide, arterial hypertension, pharmacoepidemiology.
Key words: diuretics, torasemide, arterial hypertension, pharmacoepidemiology.
Полный текст
Список литературы
1. Fukuda M, Kimura G. Pathophysiology of antihypertensive therapy with diuretics. Hypertens Res 2006; 29: 645–53.
2. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38.
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
4. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 2003; 34: 2741–9.
5. Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–4.
6. Wright JM, Musini VM. First-line drugs for hypertension. Cohrane Database Syst Rev 2009; 8; 3: CD001841.
7. Xue H, Lu Z, Tang WL et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2015; 11; 1: CD008170.
8. Mancia G, Fagard R et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
9. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр), 2010. / Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr), 2010. [in Russian]
10. Elliott W, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
11. Kent ST, Shimbo D, Huang L et al. Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010. PLoS ONE 2015; 9(8): e105888. doi:10.1371/journal.pone.0105888.
12. Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л., Галицкий А.А. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III (опрос пациентов с АГ). Системные гипертензии. 2010; 2: 33–9. / Leonova M.V., Belousov Yu.B., Shteinberg L.L., Galitskiy A.A. Results of pharmacoepidemiological study of arterial hypertension PIFAGOR III (poll of patients with AH). Systemic Hypertension. 2010; 2: 33–9. [in Russian]
13. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5–26. / Diagnosis and treatment of arterial hypertension. Russian recommendations (4th revision). Systemic Hypertension. 2010; 3: 5–26. [in Russian]
14. Girvin B, Johnston D. Diuretics: guide to properties and efficacy in hypertension. Prescriber 2010; 20 (23–24): 17–30.
15. Schmieder RE, Rockstroh JK. Efficacy of low dose loop diuretics in hypertension. Cardiology 1994; 84 (Suppl. 2): 36–42.
16. Musini VM, Rezapour P, Wright JM et al. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2012; 8: CD003825.
17. K⁄DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (Suppl. 1): S1–290.
18. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Exp Opin Pharmacother 2014; 15 (5): 605–21.
19. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 (Suppl. 3): S32–S39.
20. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121–42.
21. Coca A. Long term blood pressure control and metabolic disorders induced by torasemide in hypertension. AJH 2001; 14 (4): 116A.
22. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
2. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38.
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
4. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 2003; 34: 2741–9.
5. Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–4.
6. Wright JM, Musini VM. First-line drugs for hypertension. Cohrane Database Syst Rev 2009; 8; 3: CD001841.
7. Xue H, Lu Z, Tang WL et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2015; 11; 1: CD008170.
8. Mancia G, Fagard R et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
9. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr), 2010. [in Russian]
10. Elliott W, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
11. Kent ST, Shimbo D, Huang L et al. Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010. PLoS ONE 2015; 9(8): e105888. doi:10.1371/journal.pone.0105888.
12. Leonova M.V., Belousov Yu.B., Shteinberg L.L., Galitskiy A.A. Results of pharmacoepidemiological study of arterial hypertension PIFAGOR III (poll of patients with AH). Systemic Hypertension. 2010; 2: 33–9. [in Russian]
13. Diagnosis and treatment of arterial hypertension. Russian recommendations (4th revision). Systemic Hypertension. 2010; 3: 5–26. [in Russian]
14. Girvin B, Johnston D. Diuretics: guide to properties and efficacy in hypertension. Prescriber 2010; 20 (23–24): 17–30.
15. Schmieder RE, Rockstroh JK. Efficacy of low dose loop diuretics in hypertension. Cardiology 1994; 84 (Suppl. 2): 36–42.
16. Musini VM, Rezapour P, Wright JM et al. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2012; 8: CD003825.
17. K⁄DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (Suppl. 1): S1–290.
18. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Exp Opin Pharmacother 2014; 15 (5): 605–21.
19. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 (Suppl. 3): S32–S39.
20. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121–42.
21. Coca A. Long term blood pressure control and metabolic disorders induced by torasemide in hypertension. AJH 2001; 14 (4): 116A.
22. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
2. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38.
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
4. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 2003; 34: 2741–9.
5. Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–4.
6. Wright JM, Musini VM. First-line drugs for hypertension. Cohrane Database Syst Rev 2009; 8; 3: CD001841.
7. Xue H, Lu Z, Tang WL et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2015; 11; 1: CD008170.
8. Mancia G, Fagard R et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
9. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр), 2010. / Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr), 2010. [in Russian]
10. Elliott W, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
11. Kent ST, Shimbo D, Huang L et al. Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010. PLoS ONE 2015; 9(8): e105888. doi:10.1371/journal.pone.0105888.
12. Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л., Галицкий А.А. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР III (опрос пациентов с АГ). Системные гипертензии. 2010; 2: 33–9. / Leonova M.V., Belousov Yu.B., Shteinberg L.L., Galitskiy A.A. Results of pharmacoepidemiological study of arterial hypertension PIFAGOR III (poll of patients with AH). Systemic Hypertension. 2010; 2: 33–9. [in Russian]
13. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5–26. / Diagnosis and treatment of arterial hypertension. Russian recommendations (4th revision). Systemic Hypertension. 2010; 3: 5–26. [in Russian]
14. Girvin B, Johnston D. Diuretics: guide to properties and efficacy in hypertension. Prescriber 2010; 20 (23–24): 17–30.
15. Schmieder RE, Rockstroh JK. Efficacy of low dose loop diuretics in hypertension. Cardiology 1994; 84 (Suppl. 2): 36–42.
16. Musini VM, Rezapour P, Wright JM et al. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2012; 8: CD003825.
17. K⁄DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (Suppl. 1): S1–290.
18. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Exp Opin Pharmacother 2014; 15 (5): 605–21.
19. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 (Suppl. 3): S32–S39.
20. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121–42.
21. Coca A. Long term blood pressure control and metabolic disorders induced by torasemide in hypertension. AJH 2001; 14 (4): 116A.
22. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
________________________________________________
2. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38.
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
4. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. Stroke 2003; 34: 2741–9.
5. Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–4.
6. Wright JM, Musini VM. First-line drugs for hypertension. Cohrane Database Syst Rev 2009; 8; 3: CD001841.
7. Xue H, Lu Z, Tang WL et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2015; 11; 1: CD008170.
8. Mancia G, Fagard R et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
9. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr), 2010. [in Russian]
10. Elliott W, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
11. Kent ST, Shimbo D, Huang L et al. Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010. PLoS ONE 2015; 9(8): e105888. doi:10.1371/journal.pone.0105888.
12. Leonova M.V., Belousov Yu.B., Shteinberg L.L., Galitskiy A.A. Results of pharmacoepidemiological study of arterial hypertension PIFAGOR III (poll of patients with AH). Systemic Hypertension. 2010; 2: 33–9. [in Russian]
13. Diagnosis and treatment of arterial hypertension. Russian recommendations (4th revision). Systemic Hypertension. 2010; 3: 5–26. [in Russian]
14. Girvin B, Johnston D. Diuretics: guide to properties and efficacy in hypertension. Prescriber 2010; 20 (23–24): 17–30.
15. Schmieder RE, Rockstroh JK. Efficacy of low dose loop diuretics in hypertension. Cardiology 1994; 84 (Suppl. 2): 36–42.
16. Musini VM, Rezapour P, Wright JM et al. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2012; 8: CD003825.
17. K⁄DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (Suppl. 1): S1–290.
18. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Exp Opin Pharmacother 2014; 15 (5): 605–21.
19. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 (Suppl. 3): S32–S39.
20. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121–42.
21. Coca A. Long term blood pressure control and metabolic disorders induced by torasemide in hypertension. AJH 2001; 14 (4): 116A.
22. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
Авторы
М.В.Леонова
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
anti23@mail.ru
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
anti23@mail.ru
________________________________________________
M.V.Leonova
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
anti23@mail.ru
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
anti23@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.